Actuate Finalizes $11.0M Offering: 30.99M Shares Plus 15.49M Warrants at $0.71
ACTU is trading near its 52-week low of $0.35 (5.7% above the low).
Summary
Actuate priced an $11.0 million underwritten offering of 30,985,900 shares and 15,492,950 warrants at $0.71 per two shares, netting about $9.96 million to fund operations past a September 2026 cash runway and through Nasdaq's January 2027 compliance deadline.
Key Events · Financing and Capital Events · ACTU
-
Offering Priced at $0.71 Per Two Shares
30,985,900 shares plus 15,492,950 warrants (exercise price $0.45, five-year term) sold at $0.71 per two shares, or $0.355 per share — an 11.3% discount to the $0.40 last reported sale price on October 27, 2026.
-
Net Proceeds of $9.96 Million
Gross proceeds of $10,999,995 less a 7% underwriting discount ($770,000) and ~$268,516 in expenses leaves approximately $9,961,479; the 45-day over-allotment could add 4,647,885 shares and 2,323,942 warrants for total net proceeds of about $11,495,978.
-
Heavy Dilution to Existing Holders
The 30,985,900 new shares equal about 129% of the 24,013,577 shares outstanding as of June 30, 2026 (30,985,900 / 24,013,577 = 1.29), taking post-offering shares outstanding to 54,999,477 before any warrant exercise; new investors face $0.155 per share of net tangible book value dilution.
-
Nasdaq MVLS Deficiency Still Open
The company remains below the $50 million minimum market value of listed securities requirement after a July 15, 2026 notice, with until January 11, 2027 to regain compliance or face delisting proceedings.
Analysis · ACTU · Life Sciences
Actuate is raising $11.0 million gross ($9.96 million net) by selling 30,985,900 shares plus 15,492,950 five-year warrants at $0.45, against 24,013,577 shares outstanding as of June 30, 2026. The new shares alone equal roughly 129% of the existing base (30,985,900 / 24,013,577 = 1.29), so existing holders face heavy dilution. At a combined price of $0.71 per two shares, the effective per-share price is $0.355, an 11.3% discount to the $0.40 last reported sale price on October 27, 2026 stated in the filing. The cash matters because the Q2 10-Q showed runway only to September 2026, and the company remains out of compliance with Nasdaq's $50 million minimum market value requirement, with a January 11, 2027 compliance deadline. Proceeds go to working capital and general corporate purposes, and management says the raise funds the operating plan for at least 12 months.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 38.5% of the 1020 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACTU was trading at $0.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.9M. The 52-week trading range was $0.35 to $7.90. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.